MarketCap
Facebook
X
Telegram
Immuron Limited EBITDA | IMRN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Immuron Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.34 M | -5.8 M | -3.57 M | -2.87 M | -8.38 M | -2.91 M | -4.66 M | -3.05 M | -6.72 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.87 M | -8.38 M | -4.81 M |
Quarterly EBITDA Immuron Limited
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -5.34 M | - | -5.8 M | - | -3.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in AUD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.57 M | -5.8 M | -4.9 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Annexon
ANNX
|
-214 M | $ 4.2 | -0.71 % | $ 651 M |  USA |
 |
AbbVie
ABBV
|
15.8 B | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
557 M | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
83 K | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
-3.08 M | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
21.1 M | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
8.17 M | - | - | $ 83.9 M |  Canada |
 |
Liquidia Corporation
LQDA
|
-49.8 M | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-645 M | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
-383 M | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
-68.1 M | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
4.01 B | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-4.55 M | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-7.74 M | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
-284 M | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-10.6 M | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-9.76 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
74.8 M | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
2 B | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
TCR2 Therapeutics
TCRR
|
-150 M | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-513 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
-21.4 M | - | -60.05 % | $ 125 K | USA |
 |
Mesoblast Limited
MESO
|
-78.1 M | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
151 M | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-57.9 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
51.1 M | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-6.09 M | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
-13.3 M | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
3.04 B | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
-2.86 B | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Axcella Health
AXLA
|
-76.6 M | - | -16.42 % | $ 249 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
505 K | - | - | $ 2.02 B | USA |
 |
Intellia Therapeutics
NTLA
|
-431 M | $ 11.18 | -7.72 % | $ 1.21 B | USA |
 |
Novartis AG
NVS
|
17.6 B | $ 163.39 | -0.18 % | $ 317 B | Schweiz |
 |
Omeros Corporation
OMER
|
-122 M | $ 17.3 | -1.48 % | $ 1.1 B | USA |
 |
Oramed Pharmaceuticals
ORMP
|
-15 M | $ 3.97 | -0.75 % | $ 164 M | Israel |
 |
Tyme Technologies
TYME
|
-25.5 M | - | 8.07 % | $ 54 M | USA |
 |
Puma Biotechnology
PBYI
|
48.2 M | $ 8.13 | -3.22 % | $ 407 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
-31.5 M | $ 1.02 | -5.09 % | $ 47.3 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-3.21 M | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Pfizer
PFE
|
6.59 B | $ 29.34 | 0.36 % | $ 167 B | USA |
 |
Завод ДИОД
DIOD
|
85.9 M | - | - | - |  Russia |
 |
PainReform Ltd.
PRFX
|
-5.11 M | $ 0.78 | -4.24 % | $ 505 K | Israel |
 |
Prothena Corporation plc
PRTA
|
-214 M | $ 8.56 | -2.51 % | $ 461 M | USA |
 |
Arcus Biosciences
RCUS
|
-376 M | $ 18.66 | -1.56 % | $ 2 B | USA |
 |
Orgenesis
ORGS
|
-37.7 M | - | -33.86 % | $ 61.2 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
71.8 B | $ 14.9 | -1.03 % | $ 12.4 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
4.12 B | $ 916.16 | -0.41 % | $ 95.8 B | USA |
 |
Replimune Group
REPL
|
-317 M | $ 23.3 | 4.67 % | $ 2.16 B | USA |
 |
Фармсинтез
LIFE
|
-22.6 M | - | - | - | Russia |